Cargando…

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study

BACKGROUND: Vedolizumab registration trials were the first to include elderly patients with moderate‐to‐severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real‐life data have been reported in this population. AIMS: We investigated the effectiveness and safety of vedolizumab in matched c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pugliese, Daniela, Privitera, Giuseppe, Crispino, Federica, Mezzina, Nicolò, Castiglione, Fabiana, Fiorino, Gionata, Laterza, Lucrezia, Viola, Anna, Bertani, Lorenzo, Caprioli, Flavio, Cappello, Maria, Barberio, Brigida, Ricci, Chiara, Balestrieri, Paola, Daperno, Marco, Pluchino, Dario, Rizzello, Fernando, Scribano, Maria Lia, Sablich, Renato, Pastorelli, Luca, Manguso, Francesco, Variola, Angela, Di Sario, Antonio, Grossi, Laurino, Armuzzi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Age‐related Efficacy and Safety of Vedolizumab
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324100/ https://www.ncbi.nlm.nih.gov/pubmed/35876062 http://dx.doi.org/10.1111/apt.16923

Ejemplares similares

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease
por: Dulai, Parambir S., et al.
Publicado: (2019)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
por: Osterman, Mark T., et al.
Publicado: (2019)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
por: Danese, Silvio, et al.
Publicado: (2020)

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2022)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II
por: Lenti, Marco Vincenzo, et al.
Publicado: (2021)

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
por: Rundquist, Sara, et al.
Publicado: (2020)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves
por: Bezzio, Cristina, et al.
Publicado: (2023)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme
por: Farraye, Francis A., et al.
Publicado: (2021)

Impact of Health Insurance Expansions on Nonelderly Adults With Hypertension
por: Li, Suhui, et al.
Publicado: (2015)

Prescription Drug Use Among Elderly and Nonelderly Families
por: McKercher, Patrick L., et al.
Publicado: (2003)

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
por: Sandborn, William J., et al.
Publicado: (2021)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
por: Daperno, Marco, et al.
Publicado: (2019)

A rare case of epiploic appendagitis in a patient affected by ulcerative colitis on vedolizumab therapy
por: Pugliese, Daniela, et al.
Publicado: (2022)

Factors associated with hospitalization for seasonal influenza in a Japanese nonelderly cohort
por: Ono, Sachiko, et al.
Publicado: (2016)

Triptans Use for Migraine Headache among Nonelderly Adults with Cardiovascular Risk
por: Alwhaibi, Monira, et al.
Publicado: (2016)

Prognostic Nomograms for Nonelderly Adults with Gastric Signet Ring Cell Carcinoma
por: Wang, Hui, et al.
Publicado: (2021)

Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn’s Disease
por: Busutti, Marco, et al.
Publicado: (2023)

AF.49 DETERMINANTS OF COVID-19 VACCINE HESITANCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): RESULTS OF A NATIONAL SURVEY OF THE ITALIAN IBD PATIENTS’ ASSOCIATION (AMICI ONLUS)
por: Costantino, A., et al.
Publicado: (2021)

Vascular Calcification as a Novel Risk Factor for Kidney Function Deterioration in the Nonelderly
por: Park, Samel, et al.
Publicado: (2021)

Estimated Indirect Cost Savings of Using Telehealth Among Nonelderly Patients With Cancer
por: Patel, Krupal B., et al.
Publicado: (2023)

Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study
por: Dragoni, Gabriele, et al.
Publicado: (2023)

Medicaid Expansion and Hospitalization for Ambulatory Care–Sensitive Conditions Among Nonelderly Adults With Diabetes
por: Mondesir, Favel L., et al.
Publicado: (2019)

Comparison of 90-Day Perioperative Outcomes in Shoulder Arthroplasty Between the Elderly and Nonelderly Patients
por: Crook, Paul D., et al.
Publicado: (2018)

Elderly and Nonelderly Use of a Dedicated Ambulance Corps' Emergency Medical Services in Taiwan
por: Huang, Chien-Chia, et al.
Publicado: (2016)

Financial Burdens and Barriers to Care Among Nonelderly Adults With Heart Disease: 2010–2015
por: Bernard, Didem, et al.
Publicado: (2019)

Association between Maoto Use and Hospitalization for Seasonal Influenza in a Nonelderly Cohort in Japan
por: Yamana, Hayato, et al.
Publicado: (2021)

Implementation of Shared Decision Making for Lung Cancer Screening Among the Privately Insured Nonelderly
por: Shih, Ya-Chen Tina, et al.
Publicado: (2021)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates
por: Baker, Jillian G., et al.
Publicado: (2007)

Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease
por: Lenti, Marco Vincenzo, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Nonelderly Adult Cancer Survivors in High Deductible Health Plan: Healthcare Expenditure, Utilization and Access
por: Mahashabde, Ruchira, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3gqfs3176r388hv3bpf1e8qpns